Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?

<table>Spectral-domain optical coherence tomography (a) and time-domain optical coherence tomography (b) scans of a patient; the white star shows the subretinal fluid on spectral-domain optical coherence tomography.</table>

Journal of Ophthalmology

fig1

Figure 1

Figure 1: Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration? 

Figure 1 | Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration? 